Alteogen Inc. is a bio company located in Daejeon, South Korea. Founded in 2008, the company specializes in next-generation biologics. Their portfolio includes biobetters with improved efficacy compared to existing biologics, biosimilars that demonstrate comparability to existing biologics, and proprietary biologics. Alteogen focuses on three cutting-edge areas of the industry: long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with complexity. They have developed NexP Fusion Technology, a next-generation long-acting biobetter technology, NexMab ADC Technology, an Antibody-Drug Conjugate technology, and a novel human hyaluronidase PH 20 based on Hybrozyme Technology. Additionally, Alteogen is involved in joint development of Antibody Biosimilars with overseas strategic alliance partners.
Headquarters
305, Daejeon Bio Venture Town, 62, Yuseong-Daero 1628Beon-G, Yuseong-Gu, Daejeon
Daejeon; Daejeon;
Contact Details: Purchase the Alteogen Inc. report to view the information.
Website: http://www.alteogen.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service